Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) plunged 7.97% after the company’s topline results from the third phase DETERMINE lenabasum study in people with rare, heterogeneous autoimmune diseases dermatomyositis failed to meet the primary endpoint.  Lenabasum didn’t meet the primary endpoint At Week 28, the study’s primary endpoint, the Total Improvement […]